Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
AssigneeGenentech, Inc.
InventorsHeather MAECKER, Bryan IRVING
Life of this patent
Estimating the term…
Abstract
The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
Claims36
A method for treating or delaying progression of colorectal cancer or melanoma in an individual comprising administering to the individual an effective amount of an anti-PD-1 antibody and a MEK inhibitor, wherein the MEK inhibitor is selected from the group consisting of G02442104, G-38963, G02443714, G00039805 and GDC-0973, or a pharmaceutically acceptable salt or solvate thereof.
(canceled)
(canceled)
(canceled)
11-29:
- (canceled)
41-72:
- (canceled)
74-79:
- (canceled)
A method for treating or delaying progression of colorectal cancer in an individual comprising administering to the individual an effective amount of GDC-0973, or a pharmaceutically acceptable salt thereof, and an effective amount of an anti-PD-1 antibody.
A method for treating or delaying progression of melanoma in an individual comprising administering to the individual an effective amount of GDC-0973, or a pharmaceutically acceptable salt thereof, and an effective amount of an anti-PD-1 antibody.
Dependencies are inferred from the claim text.